Italia markets closed
FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.815,92 -570,17 (-1,49%) Nasdaq
15.657,82 -325,26 (-2,04%) Nikkei 225
38.274,05 -131,61 (-0,34%) Petrolio
80,64 -1,29 (-1,57%) Bitcoin EUR
53.951,94 -3.736,36 (-6,48%)
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Preborsa:
| Chiusura precedente | 44,64 |
| Aperto | 44,40 |
| Denaro | 0,00 x 800 |
| Lettera | 44,45 x 1200 |
| Min-Max giorno | 43,93 - 44,76 |
| Intervallo di 52 settimane | 43,93 - 69,10 |
| Volume | |
| Media Volume | 16.150.626 |
| Capitalizzazione | 89,071B |
| Beta (5 anni mensile) | 0,39 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,10 |
| Prossima data utili | 26 lug 2024 |
| Rendimento e dividendo (futuro) | 2,40 (5,46%) |
| Data ex dividendo | 04 apr 2024 |
| Stima target 1A | 53,33 |
GlobeNewswireArbutus Appoints Two New Executives
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri
© 2024 Yahoo. Tutti i diritti riservati.